Cardiovascular Outcomes of Low Testosterone

  • STATUS
    Recruiting
  • End date
    Nov 15, 2021
  • participants needed
    379
  • sponsor
    University of Colorado, Denver
Updated on 15 February 2021
body mass index
sex hormones
testosterone
testosterone level
testosterone gel

Summary

This study plans to learn more about heart and vascular aging in men. In some men as they get older, testosterone levels fall below the normal range for young men. Also, as men get older cardiovascular health worsens. This can lead to high blood pressure and heart disease. In this study we want to find out what causes cardiovascular health to worsen in older men. Also we want to find out what happens when testosterone levels are lowered for a short time. Specifically, we want to see if the reduction in cardiovascular health in older men with low testosterone levels is because of damage to mitochondria. Mitochondria are the main power supply of the cells in our body. The results from this study will help to understand why cardiovascular health declines in older men with low testosterone levels compared to younger men and older men who have higher testosterone levels. Knowing this information will help to develop therapies to prevent heart disease in men.

Description

Cardiovascular (CV) aging, featuring large artery stiffening, endothelial dysfunction, and impaired left ventricular (LV) diastolic function, is a major risk factor for the development of cardiovascular diseases (CVD). Male aging is associated with a gradual and variable decline in serum testosterone (T) and low T is associated with accelerated CV aging. The purpose of this research is to determine the key functional mechanisms underlying accelerated CV aging in older men with low T. The overall hypothesis is that mitochondrial dysfunction and oxidative stress are mechanisms underlying the apparent accelerated CV aging in older men with low T. To test this hypothesis Aim 1 will use cross-sectional comparisons of young and older men with normal T (400 ng/dl), and older men with chronically low T (<300 ng/dl). To better isolate the effects of low T from factors that change with aging and chronic low T, Aim 2 will expand on the cross-sectional comparisons by assessing measures of CV function, oxidative stress burden and mitochondrial function in older men with normal T before and after randomization to short-term (28 d) gonadal suppression (gonadotropin releasing hormone antagonist, GnRHant) + placebo (PL), GnRHant+T alone, or GnRHant+T+aromatase inhibitor (AI). AI will control for the effects of aromatization of T to estradiol (E2), and thereby isolate T effects while suppressing E2, a potent modulator of CV function. The results from this research should provide new mechanistic insight into the processes that mediate the impairment in CV function at the cellular and systemic level in older men with low T. These studies will lead to a better understanding of the independent role of T in age-related changes in CV function and the mechanisms of action, which will help guide future sex-specific therapies for the prevention of CVD.

Details
Condition Hypogonadism
Treatment Testosterone Gel, Arimidex, Placebo tablet, Placebo gel, Acyline
Clinical Study IdentifierNCT02758431
SponsorUniversity of Colorado, Denver
Last Modified on15 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 75 yrs?
Are you male?
Do you have Hypogonadism?
Do you have any of these conditions: Do you have Hypogonadism??
Do you have any of these conditions: Do you have Hypogonadism??
Do you have any of these conditions: Do you have Hypogonadism??
Men aged 18-40 years and 50-75 years
Chronically low testosterone group will have testosterone concentrations <300 ng/dl, and young and older normal testosterone groups will have testosterone levels 400-1000 ng/dl
No use of sex hormones for at least 1 year
Body mass index <40 kg/m2
Nonsmokers
Resting blood pressure <160/90 mmHg
Fasting plasma glucose <126 mg/dL
Healthy, as determined by medical history, physical examination, standard blood chemistries (chemistry panel, complete blood clot and circulating thyroid levels) and a graded exercise stress test with monitoring of blood pressure and electrocardiogram (ECG)
Sedentary or recreationally active (< 3 days/wk of vigorous aerobic exercise)
No use of medications that might influence cardiovascular function including anti-hypertensive, lipid lowering medications, and corticosteroids
No use of vitamin supplements or anti-inflammatory medications, or willing to stop 1 month prior and throughout the study

Exclusion Criteria

Contraindications to
Gonadotropin releasing hormone (GnRH) antagonist
Testosterone gel and aromatase inhibitor including hypersensitivity to Acyline, Androgel, Arimidex
Extrinsic peptide hormones, mannitol, GnRH or any other GnRH analogs
History of or active prostate or breast cancer or other sex hormone-dependent neoplasms
Pre-existing or active cardiac, renal or hepatic disease
History of stomach ulcer or bleeding
History of epilepsy or other seizure disorder
Diabetes
Active infection
Disease that affects the nervous system
Abnormal resting ECG
Additionally, men participating in the gonadal suppression intervention study
will do so with the understanding that they will be randomly assigned to study
groups that involve either GnRH antagonist plus testosterone gel plus placebo
tablet (33% chance), GnRH antagonist plus testosterone gel plus aromatase
inhibitor tablet (33% chance) or GnRH antagonist plus placebo gel plus placebo
tablet (33% chance)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note